News & Updates

The first-in-class KRAS^G12C inhibitor sotorasib significantly improved progression-free survival (PFS) in patients with previously treated non-small cell lung cancer (NSCLC) with KRAS^G12C mutations, according to results of the phase III CodeBreaK 200 trial presented at ESMO 2022.

Long-term treatment with an oral testosterone undecanoate (TU) formulation improves clinical outcomes in men with hypogonadism with no serious safety concerns, a study has shown.

Treatment with upadacitinib appears to produce improvements in ulcerative colitis (UC) symptoms as early as day 1, as shown in a recent study.

Treatments used in rheumatoid arthritis, called disease-modifying antirheumatic drugs, can also lower the risk of heart disease among patients, as shown in a recent study.

Prophylactic granulocyte-colony stimulating factor (G-CSF) results in a significant decrease both in the rate of febrile neutropaenia (FN) and duration of hospitalization for FN in breast cancer patients treated with docetaxel-based chemotherapy regimens (DBRs), according to a recent study.

Treatment with the combination of palbociclib plus bazedoxifene demonstrates clinical efficacy while having an acceptable safety profile in treatment-experienced patients with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer, according to the results of a phase Ib/II study.